Actinium Pharmaceuticals to Present at BIO-Europe® 24th Annual International Partnering Conference Nov 5, 2018
Actinium Pharmaceuticals ASH Annual Meeting Presence to Include Oral Presentation of Feasibility and Safety Results of Iomab-B Pivotal Phase 3 SIERRA Trial and also New Actimab-A Phase 2 Trial Data Nov 1, 2018
Actinium Pharmaceuticals CD33 Program to Focus on Actimab-MDS Pivotal Trial Enabling Study for Targeted Conditioning and Novel Combination Trials with Actimab-A and Venetoclax Oct 30, 2018
Actinium Pharmaceuticals to Hold Webinar Showcasing Actimab-A Post Phase 2 Trial Plans and Actimab-MDS Regulatory Update Oct 26, 2018
Actinium Pharmaceuticals Announces Participation at BIO-Europe® 24th Annual International Partnering Conference Oct 24, 2018
Actinium Pharmaceuticals Announces Webinar Showcasing Actimab-A Post Phase 2 Trial Plans and Actimab-MDS Regulatory Update Oct 22, 2018
Actinium Launches Iomab-ACT Program Offering Its Targeted, Chemo-Free, Lymphodepletion Technology as a Universal Solution to CAR-T Product Developers Oct 1, 2018
Actinium Pharmaceuticals to Host Webinar Today Introducing Next Generation Targeted Lymphodepletion Technology for CAR-T Sep 26, 2018
Actinium Pharmaceuticals to Participate in the Oppenheimer & Co. Fall Summit Focused on Specialty Pharma and Rare Disease Sep 20, 2018
Actinium Pharmaceuticals to Host Webinar Showcasing New Pipeline Initiative Focused on the CAR-T Space Sep 18, 2018
